Email this article ROLE OF ANTIBODY PRODUCTION IN THE FORMATION OF RESISTANCE TO BOTULOTOXIN A DRUGS
- Authors: Korolkova T.N1, Matytsin V.O1, Ivanov A.M2, Dovbeshko T.G1
-
Affiliations:
- I.I.Metchnikov North Western State Medical University
- S.M.Kirov Military Medical Academy
- Issue: Vol 16, No 6 (2013)
- Pages: 43-47
- Section: Articles
- URL: https://journal-vniispk.ru/1560-9588/article/view/36859
- DOI: https://doi.org/10.17816/dv36859
- ID: 36859
Cite item
Full Text
Abstract
Injections of botulotoxin A are among the most frequently used procedures in esthetic medicine. Botulo toxin A is a protein, the main mechanism of its elimination is antibody production. Hence, the production of antibodies specific to botulotoxin drugs can become the cause of botulin therapy inefficiency. However, some authors claim that the development of botulin therapy resistance is not caused by antibody production. An original method for detection of antibodies to botulotoxin A drugs is suggested, based on enzyme immu noassay. Antibodies to botulotoxin A were found in 64% of 119 patients (114 women and 5 men, mean age 40 ± 9 years), who received low-dose botulin therapy for esthetic indications (disport 60—200 Units, botox 20—100 Units). Antibodies were found in patients with good effect and with failure of therapy. Antibodies to botulotoxin A were also found in 24% donors without history of contacts with botulotoxin. The results indicate that antibody production is a factor essential for the efficiency of botulin therapy, as it can reduce its efficiency. However, antibody production is presumably not the main factor and not the only one, and further studies are needed to detect these other factors.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
T. N Korolkova
I.I.Metchnikov North Western State Medical Universityдоктор мед. наук, профессор
V. O Matytsin
I.I.Metchnikov North Western State Medical University
Email: matitsin@list.ru
кандидат мед. наук
A. M Ivanov
S.M.Kirov Military Medical Academyдоктор мед. наук, профессор
T. G Dovbeshko
I.I.Metchnikov North Western State Medical Universityассистент
References
- American Society for Aesthetic Plastic Surgery. ASAPS Statistics—Cosmetic Procedures. http://www.surgery.org/media/statistics.
- Cote T.R., Mohan A.K., Polder J.A., Walton M.K., Braun M.M. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J. Am. Acad. Dermatol. 2005; 53(3): 407—15.
- Timerbaeva S.L. Problema nejeffektivnosti lechenija i immunorezistentnosti v botulinoterapii. In’ekcionnye Metody v Kosmetologii). 2012; 1: 3—14.
- Ravichandran E., Gong Y., Fetweh H., Ancharski D.M., Joshi S.G., Simpson L.L. An initial assessment of the systemic pharmacokinetics of botulinum toxin. J. Pharmacol. Exp. Ther. 2006; 318(3): 1343—51.
- Atassi M.Z., Oshima M. Structure, activity, and immune (T and B Cell) recognition of botulinum neurotoxins. Crit. Rev. Immunol. 1999; 19(3): 219—60.
- Dressler D. Clinical relevance of botulinum toxin antibodies. Nervenarzt. 2008; 79(Suppl. 1): 36—40.
- Schrader C., Benecke R., Deuschl G., Hilker R., Kupsch A., Lange M., et al. Deep brain stimulation for dystonia: consensus recommendations of the German Deep Brain Stimulation Association. Nervenarzt. 2009; 80(6): 656—61.
- Lange O., Bigalke H., Dengler R., Wegner F., deGroot M., Wohlfarth K. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin. Neuropharmacol. 2009; 32(4): 213—8.
- Brin M.F., Comella C.L., Jankovic J., Lai F, Naumann M.; CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov. Disord. 2008; 23(10): 1353—60.
- Simpson L.L., Maksymowych A.B., Kiyatkin N. Botulinum toxin as a carrier for oral vaccines. Cell Mol. Life Sci. 1999; 56(1—2): 47—61.
- Zdanovskaia M.V., Los G., Zdanovsky A.G. Recombinant derivatives of clostridial neurotoxins as delivery vehicles for proteins and small organic molecules. J. Protein Chem. 2000; 19(8): 699—707.
Supplementary files
